Keith Kerman, MD is an Operating Partner and Senior Advisor with The Riverside Company, a global private equity firm focused on growth businesses.
Dr. Kerman has been an executive, investor, and board member at numerous healthcare businesses and organizations. Prior to joining Riverside, Dr. Kerman was a Managing Director at Primus Capital Funds and a General Partner with Morgenthaler Ventures. Dr. Kerman also was President of a division of U.S. Healthcare (now part of Aetna), was a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania, a member of the clinical faculty at the Hospital of the University of Pennsylvania, and a Senior Fellow at the Leonard Davis Institute for Health Economics at The Wharton School. Dr. Kerman has an AB and an MD from Brown University and an MBA from The Wharton School of the University of Pennsylvania.
Dr. Kerman currently is chair of the board of directors of Greenphire, a leading provider of clinical trial financial workflow software, and acting CEO of Neuradia Pharmaceuticals, a development-stage pharmaceutical company. He serves on the Mass General Brigham Innovation Growth Board, the Brown University Advisory Council on Biology and Medicine, and on the Case Western Reserve University Research & Technology Commercialization Visiting Committee.